



2016

PledPharma


Pareto Securities
Health Care Seminar
Stockholm, September 1




When the body is exposed to oxidative stress, severe damage to the nerves, liver cells and muscle tissue can occur

A semi-transparent human torso with a large yellow circle overlaid on the chest area.

**Chemotherapy
treatment**

A semi-transparent human torso with a large purple circle overlaid on the chest area.

**Paracetamol
(Acetaminophen)
poisoning**

A semi-transparent human torso with a large red circle overlaid on the chest area.

**Myocardial
infarction**



Attractive pipeline focused on high medical need

Discovery Pre-clinical Phase II Phase III Regulatory approval US/EU

Chemotherapy-induced peripheral neuropathy (CIPN)



PledOx[®]

- Phase IIb completed
- Successful EoP2 meeting with FDA and EMA

Acute liver failure following paracetamol overdose



Aladote[®]

- Preparing for clinical trial

Heart attacks



PP-099

- Phase IIa completed

PledOx[®]



Chemotherapy can cure cancer...
...but is associated with dose limiting and debilitating toxicity



Neuropathy – one of the most feared side effects of chemotherapy

- Neuropathy (nerve damage) implies numbness and tingling in hands and feet, loss of sensation, fall injuries, trouble with fine motor skills
- Interruption or dose reduction of chemotherapy is often necessary
- A majority of patients have lasting problems after completion of treatment
- There is currently no treatment available for neuropathy


40-60
percent of patients
affected ¹⁾

**High unmet
medical need**



PledOx[®] aims to become a standard pre-treatment to chemotherapy to help prevent neuropathy

PledOx[®] infusion 5 minutes before chemotherapy





PledOx[®] is currently focused on colorectal cancer and oxaliplatin with further potential

PledOx has applicability in the treatment of the most common types of cancer:

- Colorectal cancer
- Lung cancer
- Ovary
- Breast
- Pancreatic

Initial focus

PledOx can potentially be used in a broad range of platinum- and taxane-based chemotherapy regimens:

- Oxaliplatin
- Cisplatin
- Carboplatin
- Paclitaxel
- Docetaxel
- Immunotherapy


Future expansion

Further investigation



PledOx[®] could be applicable to 1.7m cancer patients


Annual applicable cancer patients¹



PledOx[®] is initially targeting 470k annual colorectal cancer patients*

PledOx[®] is expected to have efficacy in all these forms of cancer

Annual number of cycles used²



1.5m treatment cycles for colorectal cancer annually*

*(US, EU5, JP)

(1) SEER, EUCAN, GLOBOCAN.
 (2) IMS Data on unit sales of chemotherapy agents with regimen assumptions applied; no data for cisplatin in JP.



PledOx[®] – groundbreaking phase IIb trial results


“This is, to my knowledge, the first study where a treatment has been shown to reduce this kind of side effects in a clinically meaningful manner, but with no apparent negative impact on the efficacy of the chemotherapy”

Bengt Glimelius, professor emeritus in oncology at Uppsala university and primary investigator of the PLIANT-study.





Randomized, double-blind, placebo controlled phase IIb study in colorectal cancer patients




* 10 $\mu\text{mol/kg}$ (in total 11 patients).



Phase IIb-results: Clear dose-response trend in long term follow-up data

Patient-reported symptoms from nerve damage (Leonard Scale)





PledOx[®] provides clinically relevant decrease of chemotherapy induced nerve damage





PledOx[®] - an attractive first-in-class medicine

Blockbuster potential

High unmet medical need

Broad market access expected

Composition of matter patent through 2032

PledOx[®] - first in class

Significant progress

Safety and efficacy validated in phase IIb trial

Well defined regulatory pathway going forward





Paracetamol is an effective pain killer...
...but unintentional or intentional overdosing is common
and potentially lethal



An increasingly recognized problem

1,500

cases of
overdosing in
Sweden
annually

Paracetamol
BANNED
in grocery
stores

7.5g


Minimum toxic dose of
paracetamol in adults¹

10g

of paracetamol in a
normal OTC package



Paracetamol/acetaminophen overdose is the most common forms of poisoning in the US



(1) Schilling, A. M. Y., et al. "Acetaminophen: old drug, new warnings." *Cleveland Clinic journal of medicine* 77.1 (2010): 19-27.


(2) IMS, MIDAS DATA, 2013

(3) Manthripragada AD, Zhou EH, Budnitz DS, Lovegrove MC, Willy ME. Characterization of acetaminophen overdose-related emergency department visits and hospitalizations in the United States. *Pharmacoepidemiol Drug Saf.* 2011;20(8):819-26.


(4) FDA: "Acetaminophen Overdose and Liver Injury - Background and Options for Reducing Injury", (2009).



Current treatment of paracetamol overdosing requires fast admission to hospital



Estimated time since paracetamol overdose




Protective effect of current treatment (NAC) diminishes 8h post intoxication



Aladote[®] has demonstrated a protective effect beyond the NAC therapeutic window in animal models

Level of liver damage (ALT test)



Extrapolation of mice data to humans indicates efficacy of Aladote[®] also in patients arriving late to hospital



Summing up

Aiming to meet important patient needs

- Based in Stockholm, Sweden
- Listed on Nasdaq First North
- Mcap: 1,300 MSEK
- Cash position 31.7 MSEK



First-in-class compound
High unmet medical need
Groundbreaking phase IIb results
Well defined regulatory pathway going forward



First-in-class compound
High unmet medical need
Compelling preclinical data
Preparations ongoing for clinical trial



Q&A